Compare 8x8 Inc (EGHT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Moderna, Inc. — how do they compare? 8x8 Inc trades at $2 (market cap $309.09M), while Moderna, Inc. trades at $63.65 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 78.2× 8x8 Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | MRNA | |
|---|---|---|
Market Cap | $309.09M | $24.18B |
Sector | Technology | Health |
52-Week High | $2.76 | $81.80 |
52-Week Low | $1.59 | $22.36 |
Enterprise Value | $576.02M | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $1.995, down 10.94% in the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported record service revenue in Q1 2027, beating earnings estimates for the fourth consecutive quarter. Recent news highlights AI expansion and a new partner program aimed at customer growth.
The outlook is mixed: strong revenue growth and AI adoption offer upside, but high P/E of 71.33 and negative net income in 2025 pose risks. Analyst consensus is a buy with a $3.13 target, though debt levels and profitability challenges require monitoring for sustained investor confidence.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
